How 52 million-dollar push can change fate of Africa’s mothers

AFRICA: IN a rural clinic somewhere in sub-Saharan Africa, a pregnant woman sits quietly, waiting her turn.

She may not know the word preeclampsia, nor fully understand the dangers of anaemia. But the risks are real—sudden seizures, severe bleeding, even death.

For millions of women like her, pregnancy remains a journey shadowed by uncertainty.

Now, a new global health push is seeking to change that narrative—turning what has long been a story of preventable loss into one of survival and hope.

At the centre of this effort is Unitaid, which has announced a 52.5 million US dollar investment aimed at expanding access to lifesaving care for pregnant women across Africa.

The initiative, known as SUPREME (Sustained Uptake of Products for Pre-Eclampsia and Maternal Anaemia), brings together funding, innovation and on-the-ground expertise to tackle two of the continent’s most persistent maternal health threats.

Pregnancy, often celebrated as a time of joy, can quickly become life-threatening without proper care.

Preeclampsia—marked by dangerously high blood pressure—remains one of the leading causes of maternal and newborn deaths worldwide. Left untreated, it can trigger seizures, organ failure and death within hours.

Alongside it is anaemia, a condition affecting nearly 40 per cent of pregnant women globally.

Often caused by iron deficiency, anaemia increases the risk of premature birth, low birth weight and fatal complications during delivery.

What makes these conditions especially tragic is that they are both detectable and treatable.

A simple, low-cost drug like magnesium sulphate— costing less than a dollar— can cut the risk of fatal seizures in women with severe preeclampsia by more than half.

Yet in many health facilities across Africa, it remains out of reach. The challenge is not a lack of knowledge or medicine. It is the system that delivers them.

Weak supply chains, delayed diagnoses, shortages of trained health workers and inconsistent access to quality medicines continue to stand between pregnant women and the care they need.

In many cases, the right treatment exists—but arrives too late, or not at all.

This is the gap SUPREME is designed to close. Rather than introducing entirely new solutions, the initiative focuses on scaling what already works—ensuring that proven tools and emerging innovations are available, affordable and used effectively.

More than ten essential interventions will be expanded, including low-dose aspirin to prevent preeclampsia, blood pressure monitoring devices, diagnostic tools for anaemia and treatments such as intravenous iron.

The initiative will roll out across seven countries—Tanzania, Kenya, Ghana, Malawi and Senegal among them— with additional targeted interventions in Nigeria and South Africa.

It will be implemented in partnership with Amref Health Africa and the Clinton Health Access Initiative (CHAI), combining financial muscle with technical expertise.

ALSO READ: Samia’s continental call a new chapter for Africa’s maternal and child health

While CHAI focuses on ensuring the consistent supply of quality and affordable medical products, Amref will lead implementation on the ground—working with governments, health workers and communities to integrate these solutions into routine antaenatal care.

The goal is not just to deliver products, but to build systems that work—so that when a woman walks into a clinic, the care she needs is already there.

Health experts say improving maternal outcomes is not simply about increasing supply—it is about ensuring reliability.

A blood pressure monitor is only useful if it is available, functional and used correctly. A lifesaving drug matters only if it is in stock when needed.

And diagnostics are only effective if health workers are trained to interpret and act on them.

SUPREME takes a system-wide approach, tackling three critical barriers at once: availability, affordability and accessibility.

It also brings in research and technical partners to generate evidence, refine interventions and support policy changes—ensuring that successful approaches can be scaled beyond the initial countries.

The investment builds on Unitaid’s wider work in maternal and child health, including efforts to prevent postpartum haemorrhage and eliminate mother-to-child transmission of infections such as HIV, syphilis and hepatitis B.

Since its establishment in 2006, the organisation has helped unlock more than 100 health innovations, now reaching over 300 million people each year.

Yet the challenge remains immense. Across Africa, maternal mortality rates are still among the highest in the world, despite decades of global attention.

For Tanzania, where improving maternal health remains a national priority, the initiative offers a timely boost—particularly for rural and underserved areas where access gaps are most acute.

If successfully implemented, it could strengthen antaenatal care systems, improve early detection of complications and ensure timely treatment—transforming outcomes for thousands of women each year.

Ultimately, the impact of the SUPREME initiative will not be measured in dollars spent or products distributed, but in lives saved.

It will be seen in fewer emergency referrals, fewer families grieving preventable losses and more mothers returning home safely with their newborns.

Back in that rural clinic, the difference may be as simple—and as profound—as a blood pressure check, a timely diagnosis or a drug that costs less than a cup of tea.

For millions of African women, that could mean the difference between life and death—and a future where giving life no longer comes at such a high risk.